AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|
23.3 C
New York
Thursday, September 17, 2026

Tag: development

100 Years of DEKRA: Safety in a Changing World

Expert Organization Celebrated Centennial  STUTTGART, Germany, July 9, 2025 /PRNewswire/ -- June 30, 2025, DEKRA celebrated its 100th anniversary – with a clear focus on the...

Glucostra Launches Plant-Based Formula with 20 Ingredients for Natural Blood Sugar and Glucose Balance Support

Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco
Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco

Cohen & Steers Appoints Andrew Shin to lead Institutional Distribution for South Korea

HONG KONG, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Andrew Shin as Vice President, Head of...

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer

Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancerSAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"),...

CHAMPION IRON PROVIDES NOTICE OF FIRST QUARTER FY2026 RESULTS, CONFERENCE CALL AND WEBCAST DETAILS, AND DATE OF ANNUAL SHAREHOLDERS` MEETING

MONTRÉAL, July 8, 2025 /CNW/ - SYDNEY, July 9, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

Tilson Makes Significant Progress in Plan to Strengthen Business

Company Receives Final Court Approval of Key Business Continuity Motions PORTLAND, Maine, July 8, 2025 /PRNewswire/ -- Tilson Technology Management ("Tilson" or "the Company"), a...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.

New Paint Facility at Bombardier’s London Biggin Hill Service Centre Progressing to Plan as Structure Takes Shape

MONTREAL, July 08, 2025 (GLOBE NEWSWIRE) -- Bombardier announced today that the development of a new 51,000 sq. ft. paint facility at the London Biggin Hill Service Centre is progressing in earnest with several key processes completed, including ground stabilization and foundation work on the hangar. The hangar steel framework continues to progress and the cladding works have also commenced. Bromley and Biggin Hill Member of Parliament, Peter Fortune, visited the London Biggin Hill Service Centre on July 4, which provided him with a closer look at the exceptional aerospace expertise at the service centre and the development of its most recent expansion.

The Aesthetic Society Unveils New, Easier Access to On-Demand Learning Through The Aesthetic Society Academy

Netflix-style interface enhances the learning experience for Aesthetic Society and AlliedPro members—designed to advance education and support professional growth. GARDEN GROVE, Calif., July 8, 2025...

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment